Tirzepatide vs Tesamorelin

Side-by-side comparison of Tirzepatide, Tesamorelin — mechanism, dosing, half-life, side effects, and research status.

← Pick different peptides
Attribute Tirzepatide Tirzepatide (GIP/GLP-1 Dual Agonist) Weight Loss Tesamorelin Tesamorelin (GHRH Analogue) Growth Hormone
Basics
Molecular type Dual GIP/GLP-1 Receptor AgonistGHRH Analogue
Amino acids 3944
Molecular weight 4,813.5 Da5,135.8 Da
Half-life ~5 days~30 min
Route(s) Subcutaneous injectionSubcutaneous
Mechanism & Research
Primary mechanism Tirzepatide's dual mechanism differentiates it from pure GLP-1 agonists. The GIP component contributes additional appetite suppression via hypothalamic GIP receptors and improves insulin secretion efficiency. The two inc… Tesamorelin binds and activates pituitary GHRH receptors with the full-length 44-amino-acid native GHRH sequence, producing more complete pituitary signalling than the 29-amino-acid fragments (sermorelin, CJC-1295). Its …
Research status FDA Approved FDA Approved
Evidence summary Tirzepatide's clinical development programme (SURPASS for diabetes, SURMOUNT for obesity) has consistently demonstrated superior weight loss outcomes to comparator GLP-1 agonists. The SURMOUNT-1 trial set a new benchmark… Tesamorelin has the most extensive human clinical trial dataset of any GHRH analogue, accumulated during its FDA approval programme. Effects on visceral adiposity, metabolic parameters, and cognitive function have been s…
Protocol & Dosing
Typical dose 2.5mg → 15mg weekly2 mg/day
Frequency Once weeklyOnce daily
Duration Ongoing (chronic)26–52 weeks (clinical)
Timing Same day each week, any time of dayBefore breakfast or bedtime
Safety
Common side effects
  • Nausea (33–40%)
  • Diarrhoea (17–22%)
  • Vomiting (11–13%)
  • Constipation (11–12%)
  • Arthralgia (joint pain)
  • Oedema
  • Myalgia
  • Injection site redness
Contraindications
  • Personal/family history of MEN2 or medullary thyroid carcinoma
  • Known GIP or GLP-1 receptor agonist hypersensitivity
  • Severe renal impairment (caution)
  • Active malignancy
  • Pregnancy
  • Hypopituitarism
Anti-doping Not Prohibited Prohibited (WADA S2)
Deeper reading
Related peptides Semaglutide, AOD-9604, Tesamorelin CJC-1295, Sermorelin, AOD-9604
Full profile Read full Tirzepatide profile → Read full Tesamorelin profile →

Comparison data is compiled from each peptide’s individual profile. All values are drawn from peer-reviewed research and regulatory sources. For educational use only — not medical advice. Verify any protocol with a qualified healthcare provider.